- PhD and MPharm, NIPER, Dr Kandarapu
Dr Raghupathi Kandarapu is Co-Founder, CEO and Chief Scientific Officer of DelExcel Pharma Private Limited (DelExcel, Hyderabad), an integrated pharmaceutical company that provides drug development solutions to global clients, including supply of finished products. Prior to co-founding DelExcel, Dr Kandarapu was Founder and CEO of DelSync Pharma Consulting (DelSync, Hyderabad). DelSyncprovided wide range of pharmaceutical development consulting services for the registration of generic, life-cycle extension products, and 505(b)(2) category products, preclinical and clinical development activities, regulatory support, as well as project management services to global clients. Several products have been successfully managed till registration by DelSyncbetween 2015-17.
Dr Kandarapu is an alumnus of National Institute of Pharmaceutical Education and Research (NIPER, Mohali, Punjab).After completing his PhD and MPharm programs from NIPER, Dr Kandarapu spent about 14-years with major Indian pharmaceutical industries at different capacities, including Head – R&D and specialized in “Contract Pharmaceutical Development Services” business modeland successfully managed end-to-end product development services. He mentored several cross-functional teams that involved the development of generic, 505(b)(2), and NCE products for global markets.Well-versed with global regulatory requirements, eCTD preparation, regulatory filing, and regulatory communication prior and post marketing authorization.
DrKandarapu research focus includes identification and development of “proof of concept (POC)” of novel drug-delivery systems based on ‘unmet” medical need, life-cycle management (LCM) of formulations, and development of challenging modified release generic products with innovative concepts. The core area of his interest are Multi-Particulate Drug Delivery Systems (MUPS), Solid-State Characterization to identify novel salt and/or polymorphs for 505(b)(2) and/or exclusive marketing opportunities, and development of complex per-oral modified release products.